These findings indicate that a panel of circulating miRNAs may serve as a useful tool for the diagnosis and prognosis of intrahepatic cholangiocarcinoma, warranting further validation in larger cohorts. Additionally, the accuracy of diagnostic tests may be improved by increasing the sample size and including diverse clinical subgroups to enhance the robustness and generalizability of the results.
Na‐Bangchang et al. (Thu,) studied this question.